{"id":"W4417011174","doi":"10.1182/blood-2025-1905","title":"Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Brentuximab vedotin; CD30; Lymphoma; Diffuse large B-cell lymphoma; Immunohistochemistry; Rituximab; Refractory (planetary science); Clinical endpoint","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005913709,0.0003996156,0.001471138,0.0002406998,0.0001517248,0.0003368329,0.0003164454,0.0003651435,0.001399372],"category_scores_gemma":[0.0003432051,0.0001598017,0.0006363401,0.0001829598,0.0002565366,0.0002649293,0.0001621123,0.0006047586,0.0002479082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000405682,"about_ca_system_score_gemma":0.0003110894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003241168,"about_ca_topic_score_gemma":0.001136474,"domain_scores_codex":[0.9997789,0.00008905302,0.00001682945,0.00004199424,0.0000295732,0.00004365686],"domain_scores_gemma":[0.9998205,0.00003950029,0.00003823902,0.00001448286,0.000009895163,0.00007730715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6375592,0.01418159,0.0308857,0.001091828,0.001850833,0.0006164158,0.0001508751,0.002755319,0.07960016,0.000226077,0.002481638,0.2286003],"study_design_scores_gemma":[0.2325106,0.597707,0.1446073,0.0001439834,0.001901919,0.001437183,0.0001008873,0.004025746,0.01087346,0.0003750747,0.006234539,0.00008236564],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954698,0.003337489,0.0001130617,0.00008516879,0.0000402609,0.0001632599,0.00016569,0.00002650259,0.0005987583],"genre_scores_gemma":[0.9985921,0.0005195026,0.0001719223,0.00009346646,0.0000315463,0.0001090236,0.0001962203,0.000001928233,0.0002842234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001471138,"threshold_uncertainty_score":0.004681349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007496286780307536,"score_gpt":0.2359999725019607,"score_spread":0.2285036857216532,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}